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Salvage radiotherapy (SRT) represents the main treatment option for relapsing prostate 
cancer in patients after radical prostatectomy. Several open questions remain unan-
swered in terms of target volumes definition and delivered doses for SRT: the effective 
dose necessary to achieve biochemical control in the SRT setting may be different if 
the tumor recurrence is micro- or macroscopic. At the same time, irradiation of only the 
prostatic bed or of the whole pelvis will depend on the localization of the recurrence, 
local or locoregional. In the “theragnostic imaging” era, molecular imaging using positron 
emission tomography (PET) constitutes a useful tool for clinicians to define the site of 
the recurrence, the extent of disease, and individualize salvage treatments. The best 
option currently available in clinical routine is the combination of radiolabeled choline PET 
imaging and multiparametric magnetic resonance imaging (MRI), associating the nodal 
and distant metastases identification based on PET with the local assessment by MRI. A 
new generation of targeted tracers, namely, prostate-specific membrane antigen, show 
promising results, with a contrast superior to choline imaging and a higher detection 
rate even for low prostate-specific antigen levels; validation studies are ongoing. Finally, 
imaging targeting bone remodeling, using whole-body SPECT–CT, is a relevant comple-
ment to molecular/metabolic PET imaging when bone involvement is suspected.
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inTRODUCTiOn
Although radical prostatectomy (RP) with or without lymphadenectomy remains one of the main 
curative options for prostate cancer (PCa), more than 30% of the patients will relapse during follow-
up (1). Salvage radiotherapy (SRT) represents the main treatment option for relapsing patients after 
RP, and durable biochemical response rates have been reported (2). Despite gains in understanding 
how to select patients for salvage treatment, the variable clinical course of these patients still leaves 
uncertainties about how and when to appropriately manage these patients.
TABLe 1 | Summary of the most relevant tracers available for the evaluation of recurrent PCa.
Tracer Target Technique Use Site of PCa 
recurrence
Main advantage Main limitation




Established Any Sensitivity Lack of specificity 
for PCa




Sensitivity Lack of specificity 
for PCa
99mTc-diphosphonates Bone remodeling SPECT/CT Established Bone 
metastases
Sensitivity Lack of specificity 
for PCa




Any Preliminary data showing higher 




PSMA SPECT/CT Established Any Specificity Spatial resolution
PCa, prostate cancer; PSMA, prostate-specific membrane antigen.
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Early identification of relapsing disease by modern imaging 
techniques has been demonstrated to significantly influence final 
treatment decisions and drive SRT in locally or locoregionally 
relapsing patients in terms of target volume definition as well as 
planned doses. Indeed, the effective dose necessary to achieve 
biochemical control in the SRT setting may be different if the 
tumor recurrence is micro- or macroscopic (3). At the same 
time, irradiation of only the prostatic bed or of the whole pelvis 
will depend on the precise location of the recurrence, local or 
loco-regional.
In the “theragnostic imaging” era, molecular imaging using 
positron emission tomography (PET) and single-photon emis-
sion computed tomography (SPECT) constitutes a useful tool for 
clinicians to define the site of the recurrence, the extent of disease, 
and allows, therefore, for individualizing salvage treatments. In 
the following review, we report on the evidence concerning the 
use of molecular imaging in the SRT setting in patients presenting 
with biochemical relapse after RP, with a special focus on new 
PCa-specific PET tracers. Table 1 provides a summary of the most 
relevant tracers available in the setting of post-prostatectomy 
relapsing PCa.
evALUATiOn OF LOCAL AnD LYMPH 
nODe invOLveMenT ReCURRenCe BY 
CHOLine PeT TRACeRS
18F-fluorodeoxyglucose (FDG) PET imaging is a well-established 
tool in radiation therapy planning, extensively used in many 
tumor types. The lack of FDG avidity in most PCa has motivated 
the search for alternative metabolic tracers, and among them, the 
most commonly used are choline tracers. Three main choline-
based PET tracers exist, namely, 11C-choline, 18F-methylcholine, 
and 18F-ethylcholine: regardless of the slight chemical differ-
ences impacting overall distribution and the lack of formal 
comparative studies, available data suggest that their diagnostic 
performance is overall similar (4). 11C-acetate is another tracer, 
less commonly used in PCa, sharing with choline tracers a simi-
lar distribution, and being transformed to phosphatidylcholine 
after uptake (5). Studies have shown that performance is similar 
to 18F-choline (6).
The literature on the use of choline PET in recurrent PCa is 
vast but inhomogeneous, and for this reason, its use in recent 
guidelines is suggested but not established, yet. Two recent 
meta-analyses have tried to overcome this limitation, with 
encouraging and converging results when selecting studies 
with common inclusion criteria, protocols, and standard of 
reference (7, 8). Both analyses obtained pooled sensitivities and 
specificities above 85% in patients with biochemical recurrence. 
For local recurrence, in particular, the sensitivity was 61% and 
the specificity 97% (8).
Indeed, when assessing a biochemical recurrence of PCa after 
RP, it should be taken in account that the detection rates vary with 
prostate-specific antigen (PSA) levels when using choline-labeled 
tracers (9–11). Choline PET–CT has shown interesting results 
when assessing lymph node recurrences with PSA >1  ng/mL, 
with sensitivity of 90% and specificity of 100% in a per-patient 
analysis, and 67 and 96% in a per-region analysis, respectively 
(12). Below this level of PSA, the recurrence detection rate with 
choline-labeled tracers decreases, essentially because of the lack 
of ability for PET to detect small lesions (of a few millimeters), 
presenting with low metabolism due to the spatial resolution 
limit of the technique (9, 10, 13, 14). Nevertheless, the sensitivity 
of choline PET is still above 50% in patients with PSA <1 ng/
mL when PSA doubling time is <6  months or PSA velocity is 
>1 ng/mL/year (10, 15, 16). When the 1 ng/mL threshold is not 
reached and other criteria, such as PSA doubling time and veloc-
ity, are not met, prostate-targeted magnetic resonance imaging 
(MRI) is considered the best choice to detect local recurrences. 
Conventional imaging, including CT and standard MRI, is, how-
ever, of limited value to identify metastatic lymph nodes since up 
to 80% of involved lymph nodes are smaller than 1 cm (17–19), 
and the evaluation of nodal involvement in prostate MRI studies 
is limited to the pelvic field of view. Integrated whole-body cho-
line PET/MRI might thus be the modality of choice to overcome 
these limitations.
Choline PET–CT has been used to guide SRT planning, as 
recently reviewed (20). Despite the lack of large multicenter 
validation studies, single-center experiences consistently 
show that nodal and oligometastatic disease can be efficiently 
targeted (21–24). The limited spatial resolution remains the 
main obstacle for accurate targeting of the local relapse. Finally, 
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more recent evidence has shown that choline PET also has a 
prognostic value among the candidates for curative radiation 
treatment (24, 25).
The Added value of Combined PeT–MRi
Magnetic resonance imaging is the most frequently used imag-
ing modality to evaluate local PCa recurrence. T2-weighted 
imaging depicts recurrence with wide ranges of sensitivity and 
specificity with values of 48–100 and 50–100%, respectively, 
after RP and of 25–86 and 64–100%, respectively, after radiation 
therapy (26). Multiparametric imaging, such as spectroscopy, 
diffusion-weighted imaging, and dynamic contrast-enhanced 
MRI, have gained acceptance to complement T2-weighted MRI 
for primary and recurrent PCa detection (27–29). However, 
there is still an important need to further improve the accuracy 
of PCa imaging. The question arises whether associating meta-
bolic PET data with MRI might potentially enhance PCa imag-
ing. Preliminary reports using both modalities have provided 
contradictory results that could be explained in part by the dif-
ficulty to perform an accurate coregistration of the PET and MR 
images (30, 31). To solve this issue, hybrid PET–MRI systems 
have been designed to allow serial or simultaneous PET and 
MRI acquisitions during a single examination, with a common 
referential of the patient’s position. Acquiring fluorocholine PET 
and MRI in one single examination session showed a relevant 
improvement of the accuracy of PCa lesions’ detection (32–34) 
(Figure 1).
The adjunction of the PET acquisition leads to an important 
gain of the specificity of cancer detection when compared to MRI 
alone, without significant reduction of sensitivity for primary PCa 
staging. The sensitivity and specificity for the multiparametric 
MRI alone were 84.4 and 68.6%, respectively, and 81.2 and 87.1%, 
respectively, for the use of integrated PET–MRI (33). Another 
study showed that PCa was correctly detected in 80% of patients 
using 18F-choline PET alone, in 83.3% of patients using mul-
tiparametric MRI, and in 93.3% using integrated PET–MRI (34). 
These data show the ability of the PET–MRI scanner to perform 
MRI examinations of high diagnostic quality without artifacts 
related to the presence of the PET gantry and demonstrate that 
the information obtained from MRI (T2 anatomical sequences, 
diffusion, and perfusion) and PET (SUVmax) are complementary. 
Hitherto, no study has been published concerning the specific use 
of hybrid PET–MRI systems for recurrence detection or radiation 
therapy planning. However, there are ongoing studies scoping the 
development of dedicated positioning devices and dosimetric 
approaches (35, 36).
BOne MeTASTASeS ASSeSSMenT
Current guidelines recommend bone imaging only in selected 
high-risk cases. However, this definition is not homogenous 
in the literature (37, 38). In clinical practice, bone imaging is 
frequently performed in patients presenting with biochemical 
recurrence. Several choices exist, including bone scintigraphy, 
18F-NaF PET–CT, or choline-labeled (18F or 11C) PET–CT (39).
Bone scintigraphy remains a widely used imaging modality in 
the metastatic workup of PCa patients. It allows for whole-body 
screening and is highly sensitive in the detection of metastases, but 
its specificity is limited due to benign conditions presenting also 
with altered tracer uptake (e.g., degenerative joint diseases, fractures, 
infections, or benign bone tumors) (40, 41). During the last decade, 
SPECT–CT has gained a wide acceptance for bone scanning. Many 
studies have shown that SPECT–CT reduces the rate of equivo-
cal lesions compared to planar bone scan due to better anatomic 
localization of lesions and higher lesion-to-background contrast. By 
consequence, it increases diagnostic accuracy over SPECT alone or 
planar scintigraphy alone (42–46). Some authors use SPECT–CT 
only to clarify the origin of equivocal lesions based on planar 
scintigraphy, whereas others recommend to systematically acquire 
whole-body SPECT–CT from the cervical spine to the proximal 
femurs (43, 47). The proportion of indeterminate bone lesions can 
be reduced from a rate between 48 and 72% with planar whole-body 
scintigraphy and/or SPECT without CT, to a rate between 0 and 15% 
when adding SPECT with CT. Furthermore, SPECT–CT has been 
able to correctly convert a metastatic status into a non-metastatic 
status (downstaging) in 29.5% of the patients, with a sensitivity 
and specificity of 96.4 and 94.2%, respectively, on a per-patient 
analysis (47).
18F-NaF PET–CT is considered to have superior pharmacoki-
netic characteristics, such as high bone affinity, rapid clearance, 
and low protein binding, compared to 99mTc-diphosphonates. 
Its impact in PCa management has been recently evaluated 
by the National Oncologic PET Registry (NOPR) in the US, 
showing a 44% rate of change in management in recurrent 
PCa (48). The patient-based analysis showed that sensitivity 
and specificity of 18F-fluoride PET–CT and bone scan were 96 
versus 88% and 91 versus 80%, respectively (49). Although 18F-
NaF PET–CT has been reported to be more sensitive for detec-
tion of metastases than planar bone scan, the question arose 
to know whether 18F-NaF PET–CT outperforms whole-body 
SPECT–CT. Indeed, the comparative studies available hitherto 
only compare 18F-NaF PET–CT to standalone SPECT acquisi-
tions, which are intrinsically limited by the lack of anatomical 
correlation (50).
Radiolabeled choline PET–CT is used in the assessment of 
PCa recurrence in the prostate bed or in lymph nodes but can 
also highlight bone metastases (9, 14, 51). It has been reported 
that 18F-choline PET–CT was more specific than 18F-NaF PET–
CT (99 versus 93%) but that 18F-choline PET–CT suffered from 
slightly lower sensitivity (74 versus 81%) (49, 52). There is still 
an uncertainty whether these choline-negative lesions could be 
a result of androgen-deprivation therapy, since many patients 
enrolled in trials are under androgen deprivation. Based on 
this finding, it is recommended to systematically carry out 
imaging reflecting bone remodeling (18F-NaF PET–CT or 
whole-body SPECT–CT) in addition to choline PET imaging 
for bone assessment, both for diagnostic and for treatment 
planning purposes, whenever bone involvement is suspected 
clinically.
FUTURe TRACeRS
While PET imaging currently validated for clinical practice is 
based on relatively unspecific tracers, such as FDG and choline, 
FiGURe 1 | 18F-Fluorocholine hybrid PeT–MRi images showing hyperintensity on the T2-weighted sequence (A) and focal hypermetabolism (B) in a 
nodule with limited diffusion restriction on ADC map (C) and hyperperfusion (D) in a patient with a biochemical relapse (PSA = 1.75 ng/mL, doubling 
time = 11 months) 9 years after radical prostatectomy.
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ongoing research focuses on the development of new tracers 
targeting tumor-specific antigens. The most promising tracers 
for prostate imaging are summarized below. No validation 
about their use in SRT is yet available, even if this has been 
tested for prostate-specific membrane antigen (PSMA) and anti-
1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (FACBC) 
tracers (53, 54).
Prostate-Specific Membrane Antigen 
Tracers
Prostate-specific membrane antigen is a transmembrane protein 
overexpressed in PCa and highly expressed in androgen- 
independent disease (55). Preclinical and in  vitro studies sug-
gest a good specificity of this target when compared to normal 
prostatic tissue or post-radiation therapy fibrotic changes (56). 
The high specificity of this target has also motivated the devel-
opment of therapeutic or combined diagnostic/therapeutic (or 
“theragnostic”) agents, radiolabeled with 111In or 177Lu (57, 58). 
PSMA imaging is performed using 111In Capromab Pendetide 
(ProstaScint®), a monoclonal murine antibody. This tracer is 
FDA approved for staging high-risk PCa and for recurrent PCa 
post-prostatectomy. Prostascint imaging has, however, some dis-
advantages: a complex biodistribution, requiring imaging up to 
6 days after administration, an intracellular epitope, not accessible 
in living cells, non-specific signal in the presence of inflammation, 
and the intrinsic lower resolution of SPECT imaging as compared 
with PET (59).
A comprehensive description of all tracers developed in 
preclinical studies for this target goes beyond the scope of this 
paper. Therefore, we will only briefly summarize the results of 
the clinical studies performed so far in recurrent PCa. Four trac-
ers have been used in human studies, three of them using 18F as 
radioisotope and one using 68Ga.
18F-DCFBC
A dosimetry study in five metastatic patients showed the abil-
ity of the tracer to detect probable metastatic lesions in lymph 
nodes and the skeleton (60). The tracer has also been evaluated 
in primary PCa cancer characterization in 13 patients, showing a 
high specificity for tumor lesions over benign hypertrophy, even 
higher than MRI (61).
18F-BAY1075553
Only a single phase I study has been published, including 12 
patients (9 at staging and 3 with recurrent PCa), and compar-
ing the diagnostic performance of this tracer to 18F-choline, 
showing a similar performance of the two tracers for the 
characterization of prostatic lesions. However, 18F-choline has 
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been shown to be superior for nodal and bone marrow lesions’ 
detection (62).
18F-DCFPyL
Only two studies used this tracer in patients, one of them perform-
ing whole-body dosimetry and the other providing a preliminary 
comparison with 68Ga-HBED-CC in 14 patients with recurrent 
PCa (63, 64).
68Ga-HBED-CC
This is the most extensively evaluated PSMA tracer so far, with 
already over 20 published studies. All of them showed high pro-
portions of positive findings in recurrent disease, with detections 
rates ranging from 82.8 to 89.5%, in the two largest studies (65, 
66). In patients with PSA values between 0.2 and 0.5 ng/mL, the 
detection rate was 57.9% (66). One study suggests superiority 
in comparison with 18F-choline, with higher contrast and more 
lesions identified by the PSMA marker (67). Discordant results 
were found with respect to the impact of PSA doubling time on 
PET positivity (66, 68). Only one recent study has evaluated the 
impact of this tracer on radiation therapy planning, showing a 
change in strategy in about 50% of the cases, which is in line with 
the range of the management changes rate reported for choline 
(54, 69, 70).
Amino Acids
Amino acid demand and transport are increased in malignant 
prostatic cells, reflecting protein synthesis. Some radiolabeled 
amino acids have been developed in order to explore this meta-
bolic pathway. Anti-(18F)-FACBC (anti-1-amino-3-18F-FACBC 
or fluciclovine) appears to be a promising PET amino-acid 
radiotracer: it is a synthetic l-leucine analog, leucine being an 
essential nutrient for protein synthesis and cell growth, with 
high uptake in the majority of PCa lesions and metastasis. In a 
recent meta-analysis of six studies concerning the performances 
of 18F-FACBC PET–CT in patients with a suspicion of PCa recur-
rence, the pooled sensitivity and specificity for this radiotracer 
were 87 and 66%, respectively (71). Comparative studies with 
choline tracers showed a higher sensitivity and specificity, with an 
approximately 20% higher detection rate when using 18F-FACBC 
(72–75).
Gastrin-Releasing Peptide Receptors
Gastrin-releasing peptide receptors (GRPR) are overexpressed 
in a majority of PCa cells. Therefore, they represent a potential 
target for diagnostic imaging procedures. Bombesin, which 
can be labeled with positron-emitting radionuclides, is one of 
those tracers. Different radiolabeled bombesin analogs have 
been tested in primary and metastatic PCa (76, 77) as well as in 
cases of biological recurrence after surgery or hormonal therapy 
(76). Kähkönen et  al., using 68Ga-labeledDOTA-4-amino-1-
carboxymethyl-piperidine-d-Phe–Gln–Trp–Ala–Val–Gly–His–
Sta–Leu-NH2 peptide (BAY 86-7548), found satisfying results in 
detection of recurrence in prostatic bed and nodal relapse but 
poor ability to detect bone metastases (76). Sah et al. published 
a first-in-man study concerning BAY 864367, a slightly different 
18F-labeled bombesin tracer (78). They found that the tracer 
uptake was higher in primary PCa than in recurrent lesions. 
Mitsakis et  al. compared 68Ga-NODAGA-MJ9 (MJ9) PET–CT 
with 18F-flurocholine in 33 patients with recurrent PCa and 
concluded that MJ9 missed 75% of the 24 bone lesions identified 
on 18F-choline PET. However, 18% of metastatic lymph nodes 
that were positive on 18-flurocholine were negative on MJ9, and 
inversely, 13% of lesions in lymph nodes were positive on MJ9 
but negative on 18F-flurocholine PET/CT, with a greater signal-
to-background ratio on MJ9 images (79).
Fluoro-5-Dihydrotestosterone
16β-(18F)-fluoro-5-dihydrotestosterone (FDHT) is a fluorinated 
testosterone analog that can detect the overexpression of andro-
gen receptors in PCa lesions. The first study concerning the use of 
FDHT in patients with progressive metastatic PCa showed a high 
tumor-to-background ratio and a detection rate of 78% of the 59 
lesions identified on conventional imaging methods in a group 
of seven patients (80). Tumor uptake of FDHT is receptor medi-
ated (81), and thus, the results of the FDHT–PET may be able 
to predict which lesions will show a good response to androgen 
deprivation therapy and which ones will not, therefore, needing 
another type of treatment (82). Moreover, the intensity of FDHT 
uptake in bone metastases of castration-resistant PCa patients 
was a negative prognostic factor in terms of patient survival (83). 
No studies on the use of FDHT in recurrent PCa after RP have 
been published, yet.
COnCLUSiOn
The combination of radiolabeled-choline PET and MRI appears 
to be the modality of choice in clinical routine for the assessment 
of recurrence of PCa, associating the identification of nodal and 
distant disease based on PET and the local assessment by mul-
tiparametric MRI. While the availability of integrated PET–MRI 
systems will presumably remain confined to academic centers, at 
least in the near future, the use of software allowing automated 
fusion of PET and MRI sequences acquired at different times is 
already widely used in SRT planning. A new generation of tar-
geted tracers, such as PSMA and FACBC, has shown promising 
results, with a lesion-to-background contrast superior to choline 
imaging and a higher detection rate of lesions even for very 
low PSA levels. Results of ongoing validation studies are war-
ranted. Bone remodeling tracers, including standard bone scans 
with SPECT–CT, remain of great interest in assessment of bone 
extension and should be systematically associated with metabolic 
imaging.
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